Metastatic Cancer: Understanding Stage IV Disease and Treatment Options — Overview, Diagnosis & Treatment Options | MyMedicPlus

Metastatic cancer (Stage IV disease) occurs when cancer cells spread from the primary site through the bloodstream (hematogenous) or lymphatic system to distant organs. The process involves local invasion, intravasation, survival in circulation, extravasation, and colonization of a distant site. Approximately 50% of cancer patients develop distant metastases during their disease course. Common metastatic sites include lungs (most cancer types), liver (GI and breast cancers), bone (breast, prostate, lung, kidney), brain (lung, breast, melanoma, kidney), and adrenal glands.

Metastatic spread results from tumor biology, host factors, and the metastatic niche at target organs. High-grade histology, vascular invasion, large tumor size, and lymph node involvement increase metastatic risk. Molecular drivers of metastasis include EMT (epithelial-mesenchymal transition), cancer stem cell properties, and organ-specific homing (e.g., CXCR4 directs breast cancer to bone marrow). Systemic factors including inflammation, immunosuppression, and the pre-metastatic niche (organ-specific extracellular matrix and immune cell conditioning by tumor-derived exosomes) facilitate metastatic colonization.

Metastatic symptoms depend on the site of involvement. Bone metastases: bone pain, pathological fracture, hypercalcemia of malignancy, spinal cord compression. Brain metastases: headache (worse in morning), focal neurological deficit, seizures, cognitive changes, nausea. Lung metastases: dyspnea, cough, hemoptysis, pleural effusion. Liver metastases: right upper quadrant pain, jaundice (with biliary obstruction), hepatomegaly, elevated liver enzymes. Constitutional symptoms (anorexia, weight loss, fatigue) are universal in advanced metastatic disease. Malignant ascites and lymphedema indicate advanced abdominal or lymphatic involvement.

Metastatic cancer is confirmed by biopsy of the metastatic site whenever feasible, particularly for isolated or clinically uncertain lesions, to confirm malignancy, determine primary site (if unknown), and obtain molecular profiling (NGS panel, MSI/MMR, TMB, PD-L1, HER2, BRCA). Imaging: CT (chest, abdomen, pelvis), bone scan or PET-CT for skeletal involvement, MRI brain for CNS assessment. Liquid biopsy (ctDNA) provides real-time molecular profiling and monitoring. AJCC 8th edition defines M1 as distant metastasis, with site-specific M1a, M1b, M1c sub-staging in lung, breast, and prostate cancers.

Systemic therapy is the primary modality for most metastatic cancers: targeted therapy (when actionable molecular alterations are present, e.g., EGFR/ALK in NSCLC, HER2 in breast/gastric cancer, BRAF in melanoma), immunotherapy (anti-PD-1/PD-L1 across many tumor types), chemotherapy, or hormone therapy (breast, prostate). Oligometastatic disease (1-5 sites): local ablative therapy (SBRT, RFA, surgery, liver-directed TACE/SIRT) combined with systemic therapy may achieve long-term disease control. Bone metastases: zoledronic acid or denosumab for skeletal-related event prevention. Brain metastases: SRS (preferred over whole-brain RT), surgical resection for large/symptomatic lesions.

Prognosis in metastatic cancer varies enormously by primary tumor type, molecular subtype, and metastatic pattern. Modern targeted therapy and immunotherapy have transformed outcomes in many cancers: NSCLC with EGFR mutation median OS now greater than 38 months with osimertinib; melanoma with BRAF mutation 5-year OS approximately 40-52% with targeted or immunotherapy. Oligometastatic disease with aggressive local therapy achieves long-term control in subsets of patients. Tumor mutational burden (TMB) high, microsatellite instability high (MSI-H), and high PD-L1 expression predict benefit from immunotherapy across tumor types regardless of primary origin.

Surveillance after curative treatment of early-stage cancers aims to detect oligometastatic recurrence at a potentially treatable stage. Liquid biopsy (ctDNA) monitoring post-curative treatment is under active investigation as a sensitive tool for molecular recurrence detection before radiological progression. Adjuvant systemic therapy (chemotherapy, targeted therapy, immunotherapy) and adjuvant radiation reduce the risk of metastatic recurrence in high-risk localized cancers. Bone-modifying agents (bisphosphonates, denosumab) in high-risk early breast and prostate cancer reduce bone metastasis incidence. Early palliative care integration improves quality of life and may extend survival.